J&J, Merck and Novo invest in health data company

Johnson & Johnson, Merck and Novo Nordisk participated in a $150 million series E funding round for Verana Health, a digital health company that delivers data insights to drugmakers.

Advertisement

Verana Health will use the funds to expand its life sciences strategy across the drug life cycle and strengthen its database through partnerships with medical societies and other stakeholders, according to a Jan. 14 news release.

Verana will also enhance its artificial intelligence capabilities, focusing on how natural language processing can extract insights for unstructured EHR notes.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.